TrialDiabetes, obesity & metabolism2019

Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.

Melanie J Davies et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.